

### REMARKS

Claims 1-41 constitute the pending claims in the present application.

Applicants respectfully again note that the Examiner did not consider certain non-English references listed on the Form 1449 filed by the Applicants on February 19, 2003. The Applicants, as required by 37 C.F.R. §1.98 (3)(i), submitted on that Form 1449 Document **DI**, which contains an English abstract from a public database for those non-English references. Applicants believe that they failed to bring the English abstracts contained in Document **DI** to the Examiner's attention and apologize for this oversight. For the Examiner's convenience, the Applicants have again attached Document **DI**, as well as a copy of that Form 1449 to this Response as Appendix A. Applicants again respectfully request that the Examiner consider the English abstracts contained in Document **DI** and indicate that the corresponding non-English references have been examined on the Form 1449.

Applicants further note to the Examiner the commonly owned application U.S.S.N. 09/934,794, now abandoned, which may have had similar claims to those pending in the present application. Those claims were rejected by an Examiner during the pendency of that application.

Claims 36-38 are objected to under 37 C.F.R. §1.75 as being substantial duplicate of claim 35. Applicants respectfully traverse this objection. The Examiner states that "Claims 35-38 contain[ing] the exact same ingredients in a single composition. Although they are for *different use*, they are the same composition, which contain the exact same ingredients and components herein." (Emphasis Applicants.) 37 C.F.R. §1.75 (b) expressly provides for more than one claim "provided they differ substantially from one another." Further, "court decisions have confirmed applicant's right to restate (i.e. by plural claiming) the invention in a reasonable number of ways." M.P.E.P 706.03(k). Applicants assert that claims 35-38 differ substantially from one another. Applicants further assert the right to claim the invention in a reasonable number of ways, and that claims 36-38 do not represent an unreasonable number of ways. Accordingly, withdrawal of any objection under 37 C.F.R. §1.75 is respectfully requested.

Claims 13-18, 21, 23, 28, and 29 stand rejected under 35 U.S.C. §112, second paragraph. Applicants respectfully traverse this rejection. Applicants respectfully submit that the phrase “all *other* biocompatible oils that may be present” does not require antecedent basis from claim 1. (Emphasis added) The phrase is directed to biocompatible oils (if any), other than the biocompatible oil of claim 1, that may be present in the flowable pharmaceutical composition that is the subject of the rejected dependent claims. Applicants assert that the scope of claims 13-18, 21, 23, 28, and 29 is clear to one skilled in the art. Accordingly, withdrawal of the rejection under §112, second paragraph, is respectfully requested.

Claims 1-12, 27, 30-33 and 41 stand rejected under 35 U.S.C §102(b) as being anticipated by Lostritto (J. Parenter. Sci. Technol.). Applicants respectfully traverse this rejection. The Examiner asserts that Lostritto “teaches a flowable composition containing sesame oil 30% and lidocaine HCl 1%”. Applicants respectfully contend that Lostritto does not disclose a flowable composition in which the salt of an analgesic “is at most sparingly soluble” in the claimed composition, as recited in claim 1 and by reference dependent claims 2-12, 27 and 30-33.

The Examiner asserts that “lidocaine hydrochloride is the preferred herein claimed salt of the preferred herein claimed analgesic.” For clarity, Applicants respectfully note that nowhere in the instant disclosure is this salt or analgesic indicated as preferred, rather, lidocaine hydrochloride is one of the exemplary embodiments of the instant disclosure.

Further, the Examiner asserts that “products of *identical* chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical compound, the properties applicant discloses and/or claims are necessarily present.” (Emphasis Applicants). Applicants assert that Lostritto discloses a *different* chemical composition that the composition claimed in the present disclosure. The Methods section of Lostritto makes clear that the lidocaine HCl is dissolved in an aqueous solution. “Lidocaine hydrochloride is added to the external phase (0.1 M phosphate, pH = 7) and the pH readjusted to 7.0 prior to microfluidization.” (Lostritto, pg. 221). As a result, the lidocaine HCl is more than sparingly soluble in the compositions described by

Lostritto, because the salt is first dissolved in an aqueous solution prior to mixing with sesame oil.

Further, Lostritto indicates that the preparation is a submicron oil in water emulsion. (Lostritto, Abstract). As disclosed in Lostritto, the lidocaine salt is dissolved in water, resulting in a submicron emulsion. As a result, the lidocaine salt as used in Lostritto is not sparingly soluble in the Lostritto composition as a whole. Therefore, the microemulsion composition of Lostritto, consisting of lidocaine HCl dissolved in water, does not disclose the claimed compositions.

Because the lidocaine HCl is more than sparingly soluble in the Lostritto compositions, as evidenced by the fact that Lostritto first dissolves lidocaine HCl in an aqueous solution before mixing with sesame oil, and the fact that Lostritto only discloses a submicron oil in water emulsion, Applicants respectfully request reconsideration and withdrawal of this rejection for claims 1-12, 27 and 30-33.

Applicants further respectfully request reconsideration and withdrawal of the § 102(b) rejection of claim 41. The Examiner asserts that the transitional phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that *materially* affect the basic and novel characteristic[s] of the claimed invention. (Emphasis Applicants). Applicants calculate from the Methods section of Lostritto that the compositions described in Lostritto all contain over 60% water V/V: “Each emulsion contains sesame oil 30% V/V, nonionic surfactant mix 3% V/V, and sodium lauryl sulfate (0 to 1% W/V). The final lidocaine concentration used in each case is 10 mg per mL of emulsion.” Applicants assert that the transitional phrase “consisting essentially of” of claim 41 excludes a submicron emulsion that contains 60% or more water V/V, 3% nonionic surfactant V/V, and sodium lauryl sulfate (0 to 1% W/V). Because Lostritto discloses only a submicron emulsion composition, Applicants respectfully submit that Lostritto does not teach a composition with the same basic and novel characteristics as the composition claimed.

Claims 13-26, 28, 29 and 34-40 stand rejected under 35 U.S.C §103(a) as being unpatentable over Lostritto (J. Parenter. Sci. Technol.) in view of Sonne, U.S. Patent 6,193,985 ('985). Applicants respectfully traverse this rejection. Applicants respectfully submit that the

two references cited by the Examiner, taken together, do not disclose all the limitations of the rejected claims. For the reason discussed above, with respect to claims 13-26, 28, 29 and 34-38, Lostritto does not disclose all of the limitations of those claims. Further, with respect to claims 39 and 40, all of the compositions described in Lostritto contain, as best Applicants can determine as explained above, at least 60% water V/V. Accordingly, Lostritto does not anticipate claims 39 or 40 because those compositions contain "no more than 10% by weight of a solvent in which said pharmaceutically acceptable salt of said analgesic agent is at least slightly soluble."

Applicants respectfully submit that Sonne does not disclose the claim limitations that are not described by Lostritto. In the first part, Applicants have been unable to find any mention of a pharmaceutically acceptable salt in Sonne. Consequently, Sonne does not disclose the claim limitations missing from Lostritto identified above, because all those limitations concern the solubility characteristics of a pharmaceutically acceptable salt of an analgesic agent. Further, there is no disclosure in Sonne which shows or suggests an analgesic salt in oil in which the pharmaceutically acceptable salt of an analgesic agent is only sparingly soluble in a composition, as recited in claim 1 and its dependent claims. Further, there is no teaching in Sonne which shows or suggests a pharmaceutically acceptable salt of an analgesic agent with no more than 10% by weight of a solvent in which the salt is at least slightly soluble, as claims 39 and 40 recite.


In sum, this combination of references fails to disclose or suggest all the limitations of the claims rejected under U.S.C. §103(a). Accordingly, the Applicants respectfully request withdrawal of this rejection.

### **CONCLUSION**

In view of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. Early and favorable reconsideration is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at 617-832-1000. Should an extension of time be required, Applicants hereby petition for same and request that the extension fee and any other fee required for timely consideration of this application be charged to **Deposit Account No. 06-1448**.

Dated: August 26, 2003  
Patent Group  
Foley Hoag LLP  
155 Seaport Boulevard  
Boston, MA 02210  
Customer No. **29755**  
Tel.: (617) 832-1000  
Fax: (617) 832-7000

Respectfully submitted,  
FOLEY HOAG



---

Theresa C. Kavanaugh  
Registration No. 50,356  
Agent for Applicants

## Appendix A

### Doc.No.

BA

L20 ANSWER 1 OF 44 CA COPYRIGHT 2001 ACS

### **Accession Number**

134:271275 CA Full Text

### **Title**

Membrane-forming colloids for the treatment of wound

### **Inventor**

Kawanishi, Takashi; Takao, Kota; Tsuji, Yuji; Shirokane, Hideki

### **Patent Assignee/Corporate Source**

Kobayashi Pharmaceutical Co., Ltd., Japan

### **Source**

Japan Kokai Tokkyo Koho, 6 pp. CODEN: JKXXAF

### **Language**

Japanese

### **Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001097848	A2	20010410	JP 1999-280707	19990930

### **Abstract**

This invention relates to topical compns. in the form of hydrophilic colloids containing water-soluble polymers and liquefied hydrocarbons. The compns. are sprayed on an affected area and quickly form the dry coat, which can be easily washed out with water. An aerosol was formulated containing gelatin 10, tara gum 5, squalane 20, isopropylmethylphenol 4, chitin 1, fructose 20, and liquefied butane gas 40 %.

BO

L20 ANSWER 9 OF 44 CA COPYRIGHT 2001 ACS

### **Accession Number**

130:43386 CA Full Text

### **Title**

Ointments of tribenoside for treatment of hemorrhoid

### **Inventor**

Tatemichi, Hironori; Tsubakino, Miwa; Noda, Etsunosuke

### **Patent Assignee/Corporate Source**

Amafuji Pharmaceutical Co., Ltd., Japan

### **Source**

Japan Kokai Tokkyo Koho, 10 pp. CODEN: JKXXAF

### **Language**

Japanese

### **Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10316554	A2	19981202	JP 1997-139261	19970513

### **Abstract**

The ointments homogeneously contain (A) oily ointment base, (B) medium-chain triglycerides, (C) higher alcs. or waxes to give tribenoside (I) miscibility with (A), and (D) I. The ointments may contain local anesthetics, hemostatics, antibacterials, and/or antipruritics. An ointment was prepared from I 11.3, lidocaine 2.3, stearyl alc. 5, Miglyol 25, and white vaseline to 100 g. The ointment was stored at 40.degree. for 6 mo to show no change in the appearance and easiness of spreading. Enterotoxicity and antiedema efficacy of the ointment were also examined

CB

L20 ANSWER 13 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

128:119698 CA [Full Text](#)

**Title**

Oil-based local anesthetic compositions containing gelling agents for skin injury, tooth pain, etc.

**Inventor**

Samejima, Teruyuki; Kase, Naoki; Noda, Etsunosuke

**Patent Assignee/Corporate Source**

Amano Pharmaceutical Co., Ltd., Japan

**Source**

Japan Kokai Tokkyo Koho, 6 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10001441	A2	19980106	JP 1996-175743	19960614

**Abstract**

The compns. comprise a mixture of oils or oily bases miscible with the oils and gelling agents, and local anesthetics dissolved or dispersed therein. The compns. are fast-acting and long-lasting, and useful for treatment of pruritus and pain in skin injury, e.g. abrasion, cut, acne, tinea, etc., hemorrhoids, and tooth pain. Lidocaine, dextrin fatty acid esters, and hard fat were mixed to made into a suppository, which showed long-lasting anesthetic action on the cornea of guinea pigs.

CD

L20 ANSWER 16 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

125:339089 CA [Full Text](#)

**Title**

Oily base-containing compositions for protection of excreta- or tissue exudate-induced mucosa inflammation or wound worsening in the rectum or vagina

**Inventor**

Samejima, Teruyuki; Anase, Kazumasa; Oomachi, Kengo; Kase, Naotake; Noda, Etsunosuke

**Patent Assignee/Corporate Source**

Tendo Seiyaku Kk, Japan

**Source**

Japan Kokai Tokkyo Koho, 5 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08245369	A2	19960924	JP 1995-78095	19950308

**Abstract**

Oily base-containing compns. for protection of excreta- or tissue exudate-induced mucosa inflammation or wound worsening in the rectum or vagina comprise oily bases, gelling agents, and active ingredients. A suppository contained hydrocortisone acetate 5, lidocaine 30, dibucaine-HCl 5, tocopherol acetate 60, light anhydrous silica 52.5 and hard fats 1597.5 mg.

CR

**Accession Number**

123:208788 CA [Full Text](#)

**Title**

Itching-controlling agents containing calcium hydrogen phosphate particles

**Inventor**

Sugita, Kimiko; Tanaka, Shigeo; Urushizaki, Fumio

**Patent Assignee/Corporate Source**

Taisho Pharma Co Ltd, Japan

**Source**

Japan Kokai Tokkyo Koho, 4 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07173078	A2	19950711	JP 1993-321459	19931221

**Abstract**

The title agents contain itching-controlling agents (e.g. anti-inflammatory, antihistaminic, or antibacterial agents) and Ca hydrogen phosphate with particle size 0.01-1.0 mm. Antipruritus composition was formulated containing Ca hydrogen phosphate (particle size 0.25 mm) 10, EtOH 41.4, polyoxyethylene hydrogenated castor oil 2, dibucaine hydrochloride 0.3, diphenhydramine 1, dl-menthol 3.5, dl-camphor 2, and H2O 27.3, carboxyvinyl polymer 1.5 part, etc.

**CT**

**Accession Number**

117:157659 CA [Full Text](#)

**Title**

Transdermal patches for perianal diseases

**Inventor**

Yanagibashi, Norio; Kojima, Nobuo

**Patent Assignee/Corporate Source**

Lion Corp., Japan

**Source**

Japan Kokai Tokkyo Koho, 6 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04124128	A2	19920424	JP 1990-243352	19900913

**Abstract**

The title patches having an adhesive layer with peeling strength 50-300 g/50 mm width at temperature 25.degree. and relative humidity 60% and 180.degree.on an elastic support are claimed. The patches have perianal protective effect and the drugs have long-lasting effects. A composition cong. dibucaine hydrochloride 0.5, hydrocortisone acetate 0.3, ZnO 10.0, poly(acrylic acid) 4.0, poly(acrylic acid) Na salt 1.0, Na CM-cellulose 4.0, glycerin 20.0, D-sorbitol solution 10.0, synthetic hydrotalcite 0.1, polyoxyethylene sorbitan monooleate 1.0, and H2O 49.1 weight% was spread on a biaxially-stretched polyester nonwoven fabric to give a perianal patch. The patch was applied to hemorrhoid patients for 6-8 h to show local anesthetic action over 6.5-8 h and had neither uncomfortableness nor pain in peeling.



CW

L20 ANSWER 30 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

109:116063 CA [Full Text](#)

**Title**

Microemulsions containing sparingly soluble pharmaceuticals

**Inventor**

Ota, Yoichi; Suzuki, Takashi; Yagi, Eiichiro

**Patent Assignee/Corporate Source**

Shiseido Co., Ltd., Japan

**Source**

Japan Kokai Tokkyo Koho, 17 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63010717	A2	19880118	JP 1986-218825	19860917
JP 07023303	B4	19950315		

**Abstract**

A pharmaceutical microemulsion contains a sparingly soluble pharmaceutical, oils [I.O.B. (not defined) 0.22-0.85 and 0-0.2], a hydrophilic surfactant, and H<sub>2</sub>O. Dexamethasone acetate was added to diisopropyl adipate, heated, and dissolved. Olive oil and squalane were added to form an oil phase. On the other hand, polyoxyethylene stearate and lecithin were added to a mixture of propylene glycol and glycerin, followed by H<sub>2</sub>O, EtOH, and a preservative to form an aqueous phase. The oil phase was added to the aqueous phase and emulsified to give an emulsion containing 0.05- $\mu$ m particles.

CX

L20 ANSWER 32 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

108:118739 CA [Full Text](#)

**Title**

Facial day cream containing adipate and alkyl phosphates

**Inventor**

Speteanu, Rozalia; Ban, Petra; Speteanu, Ionut M.; Mihailescu, Maria; Cismaru, Stanca; Ciutacu, Ana

**Patent Assignee/Corporate Source**

Intreprinderea de Produse Cosmetice "Miraj", Rom.

**Source**

Rom., 2 pp. CODEN: RUXXA3

**Language**

Romanian

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 92020	B1	19870730	RO 1985-118050	19850319

**Abstract**

A stable facial day cream contains lanolin 2-6, 2-ethylhexyl adipate 4-5, semisynthetic glycerides 4-5, vegetable oil mono-, di-, and triglycerides 5-6, ethoxylated stearic acid 2-3, alkyl phosphate 5-6, diethylene glycol monostearate 2-3, cosmol 5, triethanolamine 0-0.05, BzOH 0.2, novocaine 0-0.005, nipagin 0.2, N,N-methylenebis[N'-(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]urea 0-0.3, hydroxyethyl- or CM-cellulose 0.2-1, perfume 0.4-1 and H<sub>2</sub>O to 100 parts by weight

CY

L20 ANSWER 33 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

108:118738 CA [Full Text](#)

**Title**

Facial night cream containing adipate and alkyl phosphates

**Inventor**

Speteanu, Rozalia; Ban, Petra; Mihailescu, Maria; Cismaru, Stanca; Speteanu, Ionut M.; Ciutacu, Ana

**Patent Assignee/Corporate Source**

Intreprinderea de Produse Cosmetice "Miraj", Rom.

**Source**

Rom., 2 pp. CODEN: RUXXA3

**Language**

Romanian

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 92019	B1	19870730	RO 1985-118051	19850319

**Abstract**

The title cosmetic contains lanolin 6, 2-ethylhexyl adipate 4, semisynthetic glycerides 5-6, vegetable oil mono-, di- and triglycerides 5-6, ethoxylated stearic acid 3, alkyl phosphate 5-6, propylene glycol 0-5, nipazin 0.2, N,N'-methylenebis[N'-(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]urea 0.3, BzOH 0.02, perfume 0.4-0.6, Bu stearate 5, novocaine 0-0.005, triethanolamine 0-0.05, vaseline 7-8, hydroxyethyl cellulose or CM-cellulose 0.2-1 and water to 100 parts by weight

CZ

L20 ANSWER 34 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

107:242630 CA [Full Text](#)

**Title**

Bases for sustained-release pharmaceutical for oral cavity application

**Inventor**

Yanagibashi, Norio; Ono, Fujio; Yanase, Tomiyuki; Ito, Hiroko

**Patent Assignee/Corporate Source**

Lion Corp., Japan

**Source**

Japan Kokai Tokkyo Koho, 6 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62142112	A2	19870625	JP 1985-280697	19851213
JP 06037386	B4	19940518		

**Abstract**

An adhesive film-forming base for sustained-release pharmaceuticals for oral cavity application is a liquid or paste containing film-forming high mol. weight substance (that are soluble in lower alcs. but insol. or hardly soluble in water) and adhesive resins dissolved in an alc. solvent. A paste for application to the oral mucosa for stomatitis treatment contained Et cellulose (100 cp) 2.0, Et cellulase (10 cp) 10.0, hydrogenated rosin 20.0, castor oil 10, triamcinolone acetone 0.005, chlorhexidine gluconate 0.8, distilled water 5.0, and EtOH 52.195%.

DC

L20 ANSWER 39 OF 44 CA COPYRIGHT 2001 ACS

**Accession Number**

104:10611 CA Full Text

**Title**

Sustained-release, topical compositions containing polyoxyethylene castor oil ether and sorbitan esters as dispersion bases

**Inventor**

Kojima, Nobuo; Yoshikawa, Masaru; Yanagibashi, Norio; Abe, Miyuki; Fukuda, Hidenori; Toda, Haruhiko

**Patent Assignee/Corporate Source**

Lion Corp., Japan

**Source**

Japan Kokai Tokkyo Koho, 10 pp. CODEN: JKXXAF

**Language**

Japanese

**Patent Information**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60149531	A2	19850807	JP 1984-5643	19840118
JP 04055165	B4	19920902		

**Abstract**

Sustained-release, topical compns. for skin or mucosa application consist of cationic surfactants and active ingredients with addition of 100 parts polyoxyethylene castor oil ether and(or) polyoxyethylene hardened castor oil ether and 3-30 parts sorbitan polyesters as dispersing bases. Thus, a topical pharmaceutical was prepared containing polyoxyethylene hardened castor oil 9, sorbitan trioleate [26266-58-0] 1, benzethonium chloride [121-54-0] 0.2, dibucaine-HCl [61-12-1] 0.1, naphazoline-HCl [550-99-2] 0.1, chlorpheniramine maleate [113-92-8] 0.2, allantoin [97-59-6] 0.1 and EtOH 10 g with addition of H2O to 100 mL.

=  
ACCESSION NUMBER: 1999:535598 CAPLUS  
DOCUMENT NUMBER: 131:149345  
TITLE: Polymethylmethacrylate microsphere composition for use  
in plastic surgery  
INVENTOR(S): Maia, Walter Jose  
PATENT ASSIGNEE(S): Brazil  
SOURCE: Braz. Pedido PI, 13 pp.  
CODEN: BPXXDX  
DOCUMENT TYPE: Patent  
LANGUAGE: Portuguese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
BR 9703142	A	19981222	BR 1997-3142	19970513 <--
AB	A compn. for use in plastic surgery is disclosed which comprises lidocaine hydrochloride 2% soln., hydroxyethyl cellulose, polymethylmethacrylate microspheres, formol 1% soln., methylparaben, and sodium thioglycolate.			

DF - Abstract

POWERED BY **Dialog**

**Medicinal formulation used for relief of muscle tension contains local anaesthetic, dwarf pine oil, camphor, horse chestnut extract and ethereal oil in water and alcohol carrier**

**Patent Assignee: BB MED PROD GMBH**

**Inventors: BEINIO H**

### Patent Family

Patent Number	Kind	Date	Application Number	Kind	Date	Week	Type
DE 20007754	U1	20000824	DE 2000U2007754	U	20000428	200053	B
FR 2808690	A3	20011116	FR 20015603	A	20010426	200201	
NL 1017929	C6	20011030	NL 20011017929	A	20010424	200211	

**Priority Applications (Number Kind Date):** DE 2000U2007754 U ( 20000428)

### Patent Details

Patent	Kind	Language	Page	Main IPC	Filing Notes
DE 20007754	U1		9	A61K-035/78	
FR 2808690	A3			A61K-035/78	
NL 1017929	C6			A61K-035/78	

### Abstract:

DE 20007754 U1

**NOVELTY** Medicinal formulation contains local anaesthetic, dwarf pine oil, camphor, horse chestnut extract and ethereal oil in a carrier comprising water and alcohol is new.

**DETAILED DESCRIPTION** Medicinal formulation contains:

- (1) 0.5-5 wt.% local anaesthetic;
- (2) 0.5-3 wt.% dwarf pine oil;
- (3) 0.5-3 wt.% camphor;
- (4) 0.05-0.5 wt.% horse chestnut extract;
- (5) 0.05-0.5 wt.% ethereal oil;
- (6) optionally additives comprising stabilisers, solubilizers, thickeners and other conventional additives and

(7) alcohol and water ad 100 wt.%.

INDEPENDENT CLAIMS are also included for the following:

(A) a medicinal fabric impregnated with the formulation and packed in foil and

(B) a roll-on stick containing the formulation which has bentonite, kaolin and/or pyrogenic silicic acid as a mineral thickener and/or polyvinylpyrrolidone, gelatin and/or a cellulose derivative as an organic thickener.

USE The formulation has a cooling and pain-relieving action and at the same time stimulates and increases blood flow and alleviates swelling. It is especially effective for the relief of tension in the calf muscles which occurs following prolonged standing or strenuous running (tired leg syndrome).

ADVANTAGE The formulation has a rapid onset of action.

pp; 9 DwgNo 0/0

**Technology Focus:**

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred formulation: The formulation has an alcohol (ethanol) content of 30-60 wt.%. The local anaesthetic is preferably menthol, although procaine or lidocaine can also be used.

The ethereal oil is especially rosemary oil and/or sage oil. The formulation contains 0.5-5 wt.% sulfonated castor oil as a solubilizer and/or a tenside, citric acid as a pH stabilizers, a benzoate and/or paraben as a preservative, bentonite, kaolin and/or pyrogenic silicic acid as a mineral thickener and/or polyvinylpyrrolidone, gelatin and/or a cellulose derivative as an organic thickener and a benzalkonium chloride as a fungicide, bactericide and/or disinfectant.


Derwent World Patents Index

© 2002 Derwent Information Ltd. All rights reserved.

Dialog® File Number 351 Accession Number 13394524

ACCESSION NUMBER: 1976:184917 CAPLUS  
 DOCUMENT NUMBER: 84:184917  
 TITLE: Composition for preventing sunburn  
 INVENTOR(S): Rheinlaender, Alfred P.  
 PATENT ASSIGNEE(S): Ger.  
 SOURCE: Ger. Offen., 12 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2507417	A1	19760318	DE 1975-2507417	19750221 <--
NL 7411764	A	19760308	NL 1974-11764	19740904
PRIORITY APPLN. INFO.: GI			NL 1974-11764	19740904



AB Compns. for preventing sunburn contained small amts. of a local anesthetic (10-50% of the amt. required to produce local anesthesia) and a liq. or paste carrier compn. For example, 0.5 g procaine-HCl (I) [51-05-8] was mixed with 99.5 g of unguentum leniens contg. white wax, spermaceti, almond oil, and H<sub>2</sub>O. A cream or emulsion (water-in-oil or oil-in-water) could also be used instead of the salve base compn.